IL143031A0 - Methods and compositions for inhibiting neoplastic cell growth - Google Patents
Methods and compositions for inhibiting neoplastic cell growthInfo
- Publication number
- IL143031A0 IL143031A0 IL14303199A IL14303199A IL143031A0 IL 143031 A0 IL143031 A0 IL 143031A0 IL 14303199 A IL14303199 A IL 14303199A IL 14303199 A IL14303199 A IL 14303199A IL 143031 A0 IL143031 A0 IL 143031A0
- Authority
- IL
- Israel
- Prior art keywords
- present
- methods
- polypeptides
- compositions
- cell growth
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4703—Inhibitors; Suppressors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus
Abstract
The present invention concerns methods and compositions for inhibiting neoplastic cell growth. In particular, the present invention concerns antitumor compositions and methods for the treatment of tumors. The invention further concerns screening methods for identifying growth inhibitory, e.g., antitumor compounds. In addition, the present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
Applications Claiming Priority (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11329698P | 1998-12-22 | 1998-12-22 | |
PCT/US1999/005028 WO1999046281A2 (en) | 1998-03-10 | 1999-03-08 | Novel polypeptides and nucleic acids encoding the same |
US13023299P | 1999-04-21 | 1999-04-21 | |
US13144599P | 1999-04-28 | 1999-04-28 | |
US13428799P | 1999-05-14 | 1999-05-14 | |
US14475899P | 1999-07-20 | 1999-07-20 | |
US14569899P | 1999-07-26 | 1999-07-26 | |
PCT/US1999/021090 WO2000015796A2 (en) | 1998-09-16 | 1999-09-15 | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
PCT/US1999/021547 WO2000015797A2 (en) | 1998-09-17 | 1999-09-15 | Compositions and methods for the treatment of immune related diseases |
PCT/US1999/028565 WO2000037638A2 (en) | 1998-12-22 | 1999-12-02 | Methods and compositions for inhibiting neoplastic cell growth |
Publications (1)
Publication Number | Publication Date |
---|---|
IL143031A0 true IL143031A0 (en) | 2002-04-21 |
Family
ID=27557838
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL14303199A IL143031A0 (en) | 1998-12-22 | 1999-12-02 | Methods and compositions for inhibiting neoplastic cell growth |
IL186154A IL186154A0 (en) | 1998-12-22 | 2007-09-20 | Methods and compositions for inhibiting neoplastic cell growth |
IL186153A IL186153A0 (en) | 1998-12-22 | 2007-09-20 | Methods and compositions for inhibiting neoplastic cell growth |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL186154A IL186154A0 (en) | 1998-12-22 | 2007-09-20 | Methods and compositions for inhibiting neoplastic cell growth |
IL186153A IL186153A0 (en) | 1998-12-22 | 2007-09-20 | Methods and compositions for inhibiting neoplastic cell growth |
Country Status (13)
Country | Link |
---|---|
EP (1) | EP1141284A2 (en) |
JP (5) | JP3993746B2 (en) |
KR (1) | KR100499600B1 (en) |
AT (2) | ATE432987T1 (en) |
AU (1) | AU768230B2 (en) |
CA (1) | CA2353799A1 (en) |
DE (2) | DE69935085T2 (en) |
DK (1) | DK1484338T3 (en) |
ES (2) | ES2327785T3 (en) |
IL (3) | IL143031A0 (en) |
MX (1) | MXPA01006330A (en) |
PT (1) | PT1484338E (en) |
WO (1) | WO2000037638A2 (en) |
Families Citing this family (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6392019B1 (en) | 1997-11-22 | 2002-05-21 | John Ford | Antibodies specific for EGF motif proteins |
US6808890B2 (en) | 1999-07-28 | 2004-10-26 | Nuvelo, Inc. | Method of detecting a cancerous cell expressing EGFL6, and EGF mutif protein |
US7419663B2 (en) | 1998-03-20 | 2008-09-02 | Genentech, Inc. | Treatment of complement-associated disorders |
US8007798B2 (en) | 1997-11-21 | 2011-08-30 | Genentech, Inc. | Treatment of complement-associated disorders |
US8088386B2 (en) | 1998-03-20 | 2012-01-03 | Genentech, Inc. | Treatment of complement-associated disorders |
US7192589B2 (en) * | 1998-09-16 | 2007-03-20 | Genentech, Inc. | Treatment of inflammatory disorders with STIgMA immunoadhesins |
AU763012B2 (en) | 1997-11-22 | 2003-07-10 | Arca Biopharma, Inc. | A novel EGF motif protein obtained from a cDNA library of fetal liver-spleen |
EP1251139A3 (en) * | 1998-04-08 | 2002-12-18 | Genentech, Inc. | Human mindin-like protein and nucleic acids encoding it |
AU4682999A (en) | 1998-06-16 | 2000-01-05 | Human Genome Sciences, Inc. | 94 human secreted proteins |
US6960433B1 (en) | 1998-10-19 | 2005-11-01 | Diadexus, Inc. | Method of diagnosing, monitoring, staging, imaging and treating prostate cancer |
WO2000042073A1 (en) | 1999-01-15 | 2000-07-20 | Biogen, Inc. | Antagonists of tweak and of tweak receptor and their use to treat immunological disorders |
EP1159419A1 (en) * | 1999-03-08 | 2001-12-05 | Genentech, Inc. | Promotion or inhibition of angiogenesis and cardiovascularization |
ES2291198T3 (en) * | 1999-07-20 | 2008-03-01 | Genentech, Inc. | COMPOSITIONS AND PROCEDURES FOR THE TREATMENT OF IMMUNOLOGICAL TYPE DISEASES. |
CA2390676A1 (en) * | 1999-12-09 | 2001-06-14 | Sankyo Company, Limited | Method of testing remedy or preventive for hyperlipemia |
EP2163561A1 (en) * | 2000-01-12 | 2010-03-17 | Yale University | NOGO receptor-mediated blockade of axonal growth |
US7119165B2 (en) | 2000-01-12 | 2006-10-10 | Yale University | Nogo receptor-mediated blockade of axonal growth |
AU5951901A (en) | 2000-05-08 | 2001-11-20 | Biogen Inc | Method for promoting neovascularization |
US7208151B2 (en) | 2001-09-12 | 2007-04-24 | Biogen Idec Ma Inc. | Tweak receptor agonists as anti-angiogenic agents |
JP4465148B2 (en) | 2000-10-06 | 2010-05-19 | イェール ユニバーシティー | Nogo receptor homolog |
US20020111302A1 (en) * | 2000-11-30 | 2002-08-15 | Y. Tom Tang | Novel nucleic acids and polypeptides |
IL164352A0 (en) | 2002-04-09 | 2005-12-18 | Biogen Idec Inc | Methods for treating tweak-related conditions |
CA2391438A1 (en) * | 2002-05-01 | 2003-11-01 | Procyon Biopharma Inc. | Psp94 diagnostic reagents and assays |
DK2529619T3 (en) | 2005-02-17 | 2016-01-11 | Biogen Ma Inc | Treatment of neurological disorders |
CA2607697C (en) | 2005-05-10 | 2015-01-06 | Biogen Idec Ma Inc. | Treating and evaluating inflammatory disorders |
WO2006138219A2 (en) | 2005-06-13 | 2006-12-28 | Biogen Idec Ma Inc. | Methods of diagnosis / prognosis of inflammatory conditions |
US7893032B2 (en) | 2005-07-07 | 2011-02-22 | Yale University | NgR variants and compositions thereof for suppressing axonal growth inhibition |
KR20170002684A (en) | 2005-11-04 | 2017-01-06 | 제넨테크, 인크. | Use of complement pathway inhibitors to treat ocular diseases |
US9044461B2 (en) | 2006-04-07 | 2015-06-02 | The Research Foundation Of State University Of New York | Transcobalamin receptor polypeptides, nucleic acids, and modulators thereof, and related methods of use in modulating cell growth and treating cancer and cobalamin deficiency |
JP5524610B2 (en) * | 2006-04-07 | 2014-06-18 | ザ リサーチ ファウンデーション オブ ステイト ユニバーシティー オブ ニューヨーク | Transcobalamin receptor polypeptides, nucleic acids and modulators thereof, and related methods used to regulate cell growth and to treat cancer and cobalamin deficiency |
US7776573B2 (en) | 2006-06-01 | 2010-08-17 | Genentech, Inc. | Crystal structure of CRIg and C3b:CRIg complex |
TWI472535B (en) | 2006-11-02 | 2015-02-11 | Genentech Inc | Humanized anti-factor d antibodies and uses thereof |
AR066660A1 (en) | 2007-05-23 | 2009-09-02 | Genentech Inc | PREVENTION AND TREATMENT OF EYE CONDITIONS ASSOCIATED WITH THEIR COMPLEMENT |
CR20170001A (en) | 2008-04-28 | 2017-08-10 | Genentech Inc | ANTI FACTOR D HUMANIZED ANTIBODIES |
ES2605471T3 (en) | 2008-05-06 | 2017-03-14 | Genentech, Inc. | Variants of matured affinity CRIg |
US9120858B2 (en) | 2011-07-22 | 2015-09-01 | The Research Foundation Of State University Of New York | Antibodies to the B12-transcobalamin receptor |
WO2015023596A1 (en) | 2013-08-12 | 2015-02-19 | Genentech, Inc. | Compositions and method for treating complement-associated conditions |
JP2017515811A (en) | 2014-05-01 | 2017-06-15 | ジェネンテック, インコーポレイテッド | Anti-factor D antibody variants and methods of use thereof |
JP2018534930A (en) | 2015-10-30 | 2018-11-29 | ジェネンテック, インコーポレイテッド | Anti-factor D antibodies and conjugates |
JP2018536650A (en) | 2015-10-30 | 2018-12-13 | ジェネンテック, インコーポレイテッド | Anti-factor D antibody variant conjugates and uses thereof |
CN114835774B (en) * | 2022-06-29 | 2022-09-27 | 中国农业大学 | Oligopeptide MSL separated from pepper seeds and application thereof in preventing or treating cancers |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ226799A (en) * | 1987-11-06 | 1991-08-27 | Oncogen | Breast cancer inhibitory factor and method for inhibiting proliferation of neoplastic cells and compositions therefor |
US5814307A (en) * | 1989-04-10 | 1998-09-29 | Bristol-Myers Squibb Company | Method for regulating cell growth, leukocyte differentiation and tumor cell growth using Oncostatin M to stimulate synthesis of IL-6 |
US5416192A (en) * | 1990-04-03 | 1995-05-16 | Bristol-Myers Squibb Company | Epithelins: novel cysteine-rich growth modulating proteins |
US5028099A (en) * | 1990-08-08 | 1991-07-02 | Bertucco Leonard J | Trash recycling container |
US6030831A (en) * | 1997-09-19 | 2000-02-29 | Genetech, Inc. | Tie ligand homologues |
WO1999055869A1 (en) * | 1998-04-27 | 1999-11-04 | Zymogenetics, Inc. | Novel polypeptide growth factors and materials and methods for making them |
SV1999000069A (en) * | 1998-06-02 | 2000-04-11 | Lilly Co Eli | ANGIOPOYETIN RELATED TO SEQUENCE OF GEN 3 IN FACE SCAR REF. X-12261 |
JP7039446B2 (en) * | 2018-11-29 | 2022-03-22 | 株式会社東芝 | Electronic device |
-
1999
- 1999-12-02 JP JP2000589692A patent/JP3993746B2/en not_active Expired - Fee Related
- 1999-12-02 ES ES07001711T patent/ES2327785T3/en not_active Expired - Lifetime
- 1999-12-02 KR KR10-2001-7007850A patent/KR100499600B1/en not_active IP Right Cessation
- 1999-12-02 DE DE69935085T patent/DE69935085T2/en not_active Expired - Lifetime
- 1999-12-02 PT PT04007617T patent/PT1484338E/en unknown
- 1999-12-02 AT AT07001711T patent/ATE432987T1/en not_active IP Right Cessation
- 1999-12-02 IL IL14303199A patent/IL143031A0/en not_active IP Right Cessation
- 1999-12-02 ES ES04007617T patent/ES2281704T3/en not_active Expired - Lifetime
- 1999-12-02 AT AT04007617T patent/ATE353339T1/en active
- 1999-12-02 DK DK04007617T patent/DK1484338T3/en active
- 1999-12-02 MX MXPA01006330A patent/MXPA01006330A/en not_active Application Discontinuation
- 1999-12-02 DE DE69940964T patent/DE69940964D1/en not_active Expired - Lifetime
- 1999-12-02 WO PCT/US1999/028565 patent/WO2000037638A2/en active Search and Examination
- 1999-12-02 AU AU17499/00A patent/AU768230B2/en not_active Expired
- 1999-12-02 EP EP99960644A patent/EP1141284A2/en not_active Withdrawn
- 1999-12-02 CA CA002353799A patent/CA2353799A1/en not_active Abandoned
-
2005
- 2005-03-10 JP JP2005066569A patent/JP4037876B2/en not_active Expired - Lifetime
- 2005-03-10 JP JP2005066570A patent/JP2005237383A/en not_active Withdrawn
-
2007
- 2007-05-24 JP JP2007138469A patent/JP2007291116A/en active Pending
- 2007-05-24 JP JP2007138468A patent/JP2007222180A/en active Pending
- 2007-09-20 IL IL186154A patent/IL186154A0/en unknown
- 2007-09-20 IL IL186153A patent/IL186153A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
DE69935085T2 (en) | 2007-08-23 |
KR100499600B1 (en) | 2005-07-07 |
JP2007291116A (en) | 2007-11-08 |
DE69940964D1 (en) | 2009-07-16 |
JP3993746B2 (en) | 2007-10-17 |
ATE432987T1 (en) | 2009-06-15 |
JP2007222180A (en) | 2007-09-06 |
IL186154A0 (en) | 2008-01-20 |
JP2003529317A (en) | 2003-10-07 |
DE69935085D1 (en) | 2007-03-22 |
WO2000037638A2 (en) | 2000-06-29 |
DK1484338T3 (en) | 2007-06-11 |
JP2005245451A (en) | 2005-09-15 |
CA2353799A1 (en) | 2000-06-29 |
ES2281704T3 (en) | 2007-10-01 |
ES2327785T3 (en) | 2009-11-03 |
EP1141284A2 (en) | 2001-10-10 |
MXPA01006330A (en) | 2002-07-02 |
IL186153A0 (en) | 2008-01-20 |
PT1484338E (en) | 2007-05-31 |
AU1749900A (en) | 2000-07-12 |
JP2005237383A (en) | 2005-09-08 |
KR20010084882A (en) | 2001-09-06 |
JP4037876B2 (en) | 2008-01-23 |
ATE353339T1 (en) | 2007-02-15 |
AU768230B2 (en) | 2003-12-04 |
WO2000037638A3 (en) | 2000-11-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL186153A0 (en) | Methods and compositions for inhibiting neoplastic cell growth | |
WO2000073348A3 (en) | Methods and compositions for inhibiting neoplastic cell growth | |
HK1114636A1 (en) | 1l-17 homologous polypeptides and therapeutic uses thereof | |
WO2002026822A3 (en) | Pumpcn compositions and uses thereof | |
IL193366A0 (en) | Fibroblast growth factor -19 | |
IL193149A (en) | Anti il-17c antibody and therapeutic compositions comprising same | |
WO2000032778A3 (en) | Methods and compositions for inhibiting neoplastic cell growth | |
KR100473550B1 (en) | Compositions and Methods for The Treatment of Tumor | |
WO2001049715A3 (en) | Methods and compositions for inhibiting neoplastic cell growth | |
WO2000037640A3 (en) | Compositions and methods for the treatment of tumor | |
EP2075335A3 (en) | Methods and compositions for inhibiting neoplastic cell growth | |
EP1873244A3 (en) | Methods and compositions for inhibiting neoplastic cell growth | |
KR100515858B1 (en) | PRO617 Polypeptides | |
KR100515857B1 (en) | PRO792 Polypeptides | |
KR100515855B1 (en) | PRO351 Polypeptides | |
KR100515856B1 (en) | PRO618 Polypeptides | |
EP1241250A3 (en) | Human dehydrogenase-like protein and nucleic acid encoding it | |
EP1865061A3 (en) | IL-17 homologous polypeptides and therapeutic uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FF | Patent granted | ||
KB | Patent renewed | ||
KB | Patent renewed | ||
KB | Patent renewed | ||
EXP | Patent expired |